D-Galactosamine (D-galN) is well established as sensitizing mice and other animals to the lethal effects of TNF, specifically, and by several orders of magnitude. Protection by anti-TNF neutralizing antibody is complete, as is (metabolically-based) protection by uridine. Sensitization occurs regardless of the origin of the released TNF, whether it is released from macrophages and/or T-cells. The same is true for the challenging agent which leads to the release of TNF, whether it is endotoxin, a superantigen, lipoprotein, bacterial DNA, or bacteria, either killed or proliferating. Most studies have utilized endotoxin as the challenging agent, and more than 70 agents have been reported to confer protection against LPS and/or TNF challenge in the model. The model has provided new insight regarding modes of protection, including from dexamethasone, which protects against challenge from LPS but not from challenge by TNF. The D-galN lethality model has also been used to test for synergistic behavior between different bacterial components, and to test for lethality when only small amounts of the challenging agent are available (lipid A chemistry).
Galanos C., Freudenberg MA, Reutter W.Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA1979; 76: 5939—5943.
2.
Lehmann V., Freudenberg MA, Galanos C.Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galN-treated mice. J Exp Med1987; 165: 657—663.
3.
Galanos C., Freudenberg MATumor necrosis factor mediates endotoxin shock: the protective effects of antibodies and cortisone. In: Bonavida B, Granger G. (eds) Tumor Necrosis Factor: structure, mechanism of action, role in disease and therapy. Basel : Karger, 1990; 187—193.
4.
Galanos C., Freudenberg MA, Coumbos A., Matsuura M., Lehmann V., Bartholeyns J.Induction of lethality and tolerance by endotoxin are mediated by macrophages through tumor necrosis factor. In: Bonavida B, Gifford GE, Kirchner H, Old LJ. (eds) Tumor Necrosis Factor/Cachectin and Related Cytokines. Basel: Karger, 1987; 114—127.
5.
Freudenberg MA, Keppler D., Galanos C.Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun1986; 51: 891—895.
6.
Freudenberg MA, Galanos C.Induction of tolerance to lipopolysaccharide (LPS)-D-galN lethality by pretreatment with LPS is mediated by macrophages . Infect Immun1986; 56: 1352—1357.
7.
Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, Mergenhagen SEThe primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis1980; 141: 55—63.
8.
Galanos C., Freudenberg MA, Katschinski, Salomao R., Mossmann H., Kumazawa Y.Tumor necrosis factor and host response to endotoxin. In: Ryan JL, Morrison DC. (eds) Bacterial Endotoxic Polysaccharide, vol II. Boca Raton, FL: CRC Press, 1992; 75—104.
9.
Brown DE, Morrison DCPossible alteration of normal mechanisms of endotoxin toxicity in vivo by actinomycin D. J Infect Dis1982; 146: 746—750.
10.
Selye H., Tuchweber B., Bertok L.Effect of lead acetate on the susceptibility of rats to bacterial endotoxin . J Bacteriol1966; 91: 884—890.
11.
Rippe DF, Berry LJMetabolic manifestations of lead acetate sensitization to endotoxin in mice . J Reticuloendothel Soc1973; 13: 527—535.
12.
Shands Jr JW, Miller V., Martin H.The hypoglycemic activity of endotoxin. I. Occurrence in animals hyperreactive to endotoxin. Proc Soc Exp Biol Med1969; 130: 413—417.
13.
Decker K., Keppler D.Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogensesis of cell injury and cell death. Rev Physiol Biochem Pharmacol1974; 71: 77—106.
14.
Matthys P., Mitera T., Heremans H., Van Damme J, Billiau A.Anti-gamma interferon and anti-interleukin-6 antibodies after staphylococcal enterotoxin D-induced weight loss, hypoglycemia, and cytokine release in D-galN-sensitized and unsensitized mice. Infect Immun1995; 63: 1158—1164.
15.
Bonventre PF , Heeg H., Edwards CK, Cullen CMA mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity. Infect Immun1995; 63: 509—515.
16.
Aoki Y., Hiromatsu K., Kobayashi N. et al. Protective effect of granulocyte colony-stimulating factor against T-cell mediated lethal shock triggered by superantigens. Blood1995; 86: 1420—1427.
Nagaki M., Muto Y., Ohnishi H. et al. Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B. Gastroenterology1994; 106: 450—458.
19.
Miethke T., Wahl C., Heeg K., Wagner H.Acquired resistance to superantigen-induced T cell shock. V beta selective T cell responsiveness unfolds directly from a transient state of hyperreactivity . J Immunol1993; 150: 3776—3884.
20.
Chapes SK, Beharka AALipopolysaccharide is required for the lethal effects of enterotoxin B after D-galN sensitization. J Endotoxin Res1995 ; 2: 263—271.
21.
Yasuda S., Nagaki M., Moriwaki H.Staphylococcal enterotoxin B induces hepatic injury and lethal shock in endotoxin-resistant C3H/HeJ mice despite a deficient macrophage response. J Endotoxin Res2002; 8: 253—261.
22.
Blank C., Luz A., Bendigs S., Erdmann A., Wagner H., Heeg K.Superantigen and endotoxin synergize in the induction of lethal shock. Eur J Immunol1997; 27: 825—833.
23.
Miethke T., Duschek K., Wahl C., Heeg K., Wagner H.Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol1993; 23: 1494—1500.
24.
Miethke T., Wahl C., Heeg K., Echtenacher B., Krammer PH, Wagner H.T cell mediated lethal shock triggered by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med1992; 175: 91—98.
25.
Bate CA, Taverne J., Playfaur JHDetoxified exoantigens and phosphatidylinositiol derivatives inhibit tumor necrosis factor induction of malarial exoantigens. Infect Immun1992; 60: 1894—1901.
26.
Hellman J., Roberts Jr JD, Tehan MM, Allaire JE, Warren HSBacterial peptidoglycan-associated lipoprotein is released into the bloodstream in Gram-negative sepsis and causes inflammation and death in mice. J Biol Chem2002; 277: 14274—14280.
27.
Zhang H., Peterson JW, Niesel DW, Klimpel GRBacterial lipoprotein and lipopolysaccharide act synergistically to induce lethal shock and proinflammatory cytokine production. J Immunol1997; 159: 4868—4878.
28.
Galanos C., Gumenscheimer M., Mühlradt PF, Jirillo E., Freudenberg MAMALP-2, a Mycoplasma lipopolypeptide with classical endotoxic properties: end of an era of LPS monopoly?J Endotoxin Res2000, 6: 471—476.
29.
Sparwasser T., Miethke T., Lipford G. et al. Bacterial DNA causes septic shock. Nature1997; 386: 336—337.
30.
Cornelie S. , Wiel E., Lund N. et al. Cytosine-phosphate-guanine (CpG) motifs are sensitizing agents for lipopolysaccharide in toxic shock model. Intensive Care Med2002; 9: 1340—1347.
31.
Heeg K., Sparwasser T., Lipford GB, Hacker H., Zimmermnan S., Wagner H.Bacterial DNA as an energetically conserved signalling danger of infection to immune cells. Eur J Clin Microbiol Infect Dis1998; 7: 464—469.
32.
Sparwasser T., Miethke T., Lipford G. et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor αmediated shock. Eur J Immunol1997; 27: 1671—1679.
33.
Freudenberg MA, Galanos C.Tumor necrosis factor alpha mediates lethal activity of killed Gram-negative and Gram-positive bacteria in D-galN-treated mice. Infect Immun1991; 59: 2110—2115.
34.
Silverstein R., Norimatsu M., Morrison DCFundamental differences during Gram-positive versus Gram-negative sepsis become apparent during bacterial challenge of D-galN-treated mice. J Endotoxin Res1997; 4: 173—181.
35.
Silverstein R., Wood JG, Xue Q., Norimatsu M., Horn DL, Morrison DCDifferential host inflammatory responses to viable versus antibiotic-killed bacteria in experimental microbial sepsis . Infect Immun2000; 68: 2301—2308.
36.
Silverstein R., Johnson DCEndogenous and exogenous glucocorticoid responses to experimental bacterial sepsis. J Leukoc Biol2003; 73: 417—427.
37.
Silverstein R., Gao JJ, Xue Q., Morrisom DCThe role of TNF-a in enterococcal infection in D-galactosamine treated mice. Shock2002 ; 155: 24(Abstract #70).
38.
Papasian CJ , Silverstein R., Gao JJ, Bamberger DM, Morrison DCAnomalous role of tumor necrosis factor alpha in experimental enterococcal infection. Infect Immun2002; 70: 6628—6637.
39.
Silverstein R., Christoffersen CA, Morrison DCModulation of endotoxin lethality in mice by hydrazine sulfate. Infect Immun1989; 57: 2072—2078.
40.
Silverstein R., Turley BR, Christofferesen CA, Johnson DC, Morrison DCHydrazine sulfate protects D-galN-sensitized mice against endotoxin and tumor necrosis factor/cachectin lethality: evidence of a role for the pituitary. J Exp Med1991; 173: 357-365.
41.
Silverstein R.Uridine protection against D-galN-sensitized LPS lethality in mice is complete. J Endotoxin Res1997; 4: 463—465.
42.
Marino MW, Dunn A., Grail D. et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA1997; 94: 8093—8098.
43.
Glaccum MB, Stocking KL, Charrier K. et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol1997 ; 159: 3364—3371.
44.
Garcia I., Miyazaki Y., Araki K. et al. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections . Eur J Immunol1995; 25: 2401—2407.
45.
Rothe J., Lesslauer W., Lötscher H. et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes . Nature1993; 364: 798—802.
46.
Erickson SL, de Sauvage FJ, Kikly K. et al. Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature1994; 372: 560—563.
47.
Kolls JK, Lei D., Nelson S. et al. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis1995; 171: 570—575.
48.
Xu H., Gonzalo JA, St Pierre Y. et al. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med1994; 180: 95—109.
49.
Essani NA, Fisher MA, Farhood A., Manning AM, Smith CW, Jaeschke H.Cytokine-induced upregulation of hepatic intercellular adhesion molecule-1 messenger RNA expression and its role in the pathology of murine endotoxin shock and acute liver failure. Hepatology1995; 21: 1632—1639.
50.
Jaeschke H. , Essani NA, Fisher MA, Vonderfecht SL, Farhood A., Smith CWRelease of soluble intercellular adhesion molecule 1 into bile and serum in murine endotoxin shock. Hepatology1996; 23: 530—536.
51.
Essani NA, Bajt ML, Farhood A., Vonderfecht SL, Jaeschke H.Transcriptional activation of vascular cell adhesion molecule-1 gene in vivo and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J Immunol1997; 158: 5941—5948.
52.
Chosay JG, Fisher MA, Farhood A., Ready KA, Dunn CJ, Jaeschke H.Role of PECAM-1 (CD13) in neutrophil transmigration in murine models of liver and peritoneal inflammation. Am J Physiol1998; 274: G776—G782.
53.
Klintman D. , Schramm R., Menger MD, Thorlacius.Leukocyte recruitment in hepatic injury: selectin-mediated leukocyte rolling is a prerequisite for CD18-dependent firm adhesion. J Hepatol2002; 36: 53—59.
54.
Essani NA, Fisher MA, Simmons CA, Hoover JL, Farhood A., Jaeschke H.Increased P-selectin gene expression in the liver vasculature and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J Leukoc Biol1998; 63; 288—296.
55.
Ohuchi T., Tada K., Akamatsu K.Endogenous ET-1 contributes to liver injury induced by galactosamine and endotoxin in isolated perfused rat liver. Am J Physiol1995; 268: G997—G1003.
56.
Shindo T., Kurihara H., Kurihara Y., Morita H., Yazaki Y.Upregulation of endothelin-1 and adrenomedullin gene expression in the mouse endotoxin shock model. J Cardiovasc Pharmacol1998; 31 (Suppl 1): S541—S544.
57.
Tiegs G., Niehörster, Wendel A.Leukocyte alterations do not account for hepatitis induced by endotoxin or TNF-α in galactosamine-sensitized mice. Biochem Pharmacol1990; 40: 1317—1322.
58.
Silverstein R., Johnson WM, Bucklin SE, Johnson DCThe protein kinase C activator PMA modulates LPS lethality in normal mice and protects against LPS lethality in D-galN-sensitized mice. J Endotoxin Res1996; 3: 29—37.
59.
Amura CR, Silverstein R., Morrison DCMechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro activation studies. Infect Immun1998; 66: 5372—5378.
60.
Cusumano V. , Mancuso G., Genovese F. et al. Neonatal hypersensitivity to endotoxin correlates with increased tumor necrosis factor production in mice. J Infect Dis1997; 176: 168—176.
61.
Lehner MD, Morath S., Michelsen KS, Schumann RR, Hartung T.Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators . J Immunol2001; 166: 5161—5167.
62.
Gao JJ, Xue Q., Papasian CJ, Morrison DCBacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol2001; 166: 6855—6860.
63.
Wray GM, Foster SJ, Hinds CJ, Thiemermann C.A cell wall component from pathogenic and non-pathogenic Gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-α, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat. Shock2001; 15: 135—142.
64.
Gao JJ, Zuvanich EG, Xue Q., Horn DL, Silverstein R., Morrison DCBacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol1999; 163: 4095—4099.
65.
Gao JJ, Diesl V., Wittmann T. et al. Bacterial LPS and CpG DNA differentially induce gene expression in mouse macrophages. J Endotoxin Res2003 ; 9: 237—243.
66.
Yang S., Tamai R., Akashi S. et al. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun2001; 69: 2045—2053.
67.
Wang JE, Jørgensen PF, Ellingsen EA et al. Peptidoglycan primes for LPS-induced release of proinflammatory cytokines in whole human blood. Shock2001 ; 16: 178—182.
68.
Proceedings of the Symposium: Antibiotic-mediated endotoxin release — Contribution to pathogenesis in Gram-negative sepsis. J Endotoxin Res1995; 3: 171—279.
69.
Bucklin SE, Morrison DCDifferences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J Infect Dis1995; 172: 1519—1527.
70.
Morrison DC , Bucklin SE, Leeson MC, Norimatsu M.Contribution of soluble endotoxin released from Gram-negative bacteria by antibiotics to the pathogenesis of experimental sepsis in mice. J Endotoxin Res1996; 3: 237—243.
71.
Bucklin SE, Morrison DCBacteremia versus endotoxemia in experimental mouse leukopenia — role of antibiotic chemotherapy. J Infect Dis1996 ; 174: 1249—1254.
72.
LeRoy D., Morand P., Lengacher S. et al. Streptococcus mitis cell walls and lipopolysaccharide induce lethality in D-galactosamine-sensitized mice by a tumor necrosis factor-dependent pathway. Infect Immun1996; 64: 1846—1849.
73.
Deiters U., Gumenscheimer M., Galanos C., Mühlradt PFToll-like receptor 2- and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses. Infect Immun2003; 71: 4456—4462.
74.
Freudenberg MA, Salômao, Sing A., Mitov I., Galanos C.Reconciling the concepts of endotoxin sensitization and tolerance. Prog Clin Biol Res1998; 397: 261—268.
Silverstein R. , Johnson DC, Norimatsu M.Glucocorticoid control of endotoxin responses . In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York: Dekker, 1999; 769—779.
Libert C., Hochepied T., Berger FG, Baumann H., Fiers W., Brouckaert P.High-level constitutive expression of alpha 1-acid glycoprotein and lack of protection against tumor necrosis factor-induced lethal shock in transgenic mice. Transgenic Res1998; 7: 429—435.
79.
Libert C., Van Molle W, Brouckaert P., Fiers W.Platelet-activating factor is a mediator in tumor necrosis factor/galactosamineinduced lethality. J Inflamm1995; 46: 139—143.
80.
Libert C., Brouckaert P. Fiers W.Protection by alpha 1-acid glycoprotein against tumor necrosis factor-induced lethality. J Exp Med1994; 180: 1571—1575.
81.
Wang R., Fang Q., Zhang L. et al. CD28 ligation prevents toxin-induced septic shock in mice by inducing IL-10 expression. J Immunol1997; 158: 2856—2861.
82.
Field SK, Morrison DCAn anti-idiotype antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge from endotoxin. Infect Immun1994; 62: 3994—3999.
83.
Mandine E., Salles MF, Zalisz R., Guenounou M., Smets P.Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniae. Infect Immun1990; 58: 2828—2833.
84.
Gallay P., Heumann D., Le-Roy D., Barras C., Glausner MPMode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci USA1994; 91: 7922—7926.
85.
Ramachandra RN, Berczi A., Schon AH, Berczi I.Inhibition of lipid-A and lipopolysaccharide-induced cytokine secretion, B cell mitogenesis, and lethal shock by lipid A-specific murine monoclonal antibodies. J Infect Dis1993; 167: 1151—1159.
86.
Vacheron F. , Mandine E., Lenaour R., Smets P., Zalisz R., Guenounou M.Inhibition of production of tumor necrosis factor by monoclonal antibodies to lipopolysaccharides. J Infect Dis1992; 165: 873—878.
87.
Bailat S., Heumann D., Le-Roy D. et al. Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice. Infect Immun1997; 65: 811—814.
88.
Morrison DC , Silverstein R., Bright SW, Chen TY, Flebbe LM, Lei M-G.Monoclonal antibody to mouse lipopolysaccharide receptor protects mice against the lethal effects of endotoxin. J Infect Dis1990; 162: 1063—1068.
89.
Piguet PF, Vesin C., Ryser JE et al. An effector role for platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a CD11a- and CD54-dependent interaction with endothelium. Infect Immun1993; 61: 4182—4187.
90.
Fiedler VB, Loof I., Sander E., Voehringer V., Galanos C., Fournel MAMonoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med1992; 120: 574—588.
91.
Grau GE, Vesin C., De-Groote D. et al. Prevention of human TNF-induced cutaneous Schwartzmann reaction and acute mortality in mice treated with anti-human TNF monoclonal antibodies . Clin Exp Imm unol199 1; 84: 411—414.
92.
Libert C., Van-Molle W., Brouckaert P., Fiers W.Alpha 1-antitrypsin inhibits the lethal response to TNF in mice. J Immunol1996; 157: 5126—5129.
93.
Kirikae T., Hirata M., Yamasu H. et al. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)derived peptide against murine endotoxemia. Infect Immun1998; 66: 1861—1868.
94.
Bals R., Weiner DJ, Moscioni AD, Meegalla RL, Wilson JMAugmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun1999; 67: 6084—6089.
95.
Furusako S. , Takahashi T., Mori S. et al. Protection of mice from LPS-induced shock by CD14 antisense oligonucleotide. Acta Med Okayama2001; 55: 105—115.
96.
Maruyama H. , Kikuchi S., Kawaguchi B. et al. Suppression of lethal toxicity of endotoxin by biscoclaurine alkaloid cepharanthin. Shock2000; 13: 160—165.
97.
Hirata N., Hiramatsu K., Kishi K., Yamasaki T., Ichimiya T., Nasu M.Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother2001; 45: 2638—2642.
Chae MR, Park BH, Kim JS, Rho HW, Park JW, Kim HRProtective effect of C-reactive protein against the lethality induced by Vibrio vulnificus lipopolysaccharide. Microbiol Immunol2000; 44: 335—340.
100.
Elliot GT, Welty D., Kuo YDThe D-galactosamine loaded mouse and its enhanced sensitivity to lipopolysaccharide and monophosphoryl lipid A: a role for superoxide. J Immunother1991; 10: 69—74.
101.
Parry EWCycloheximide or nordihydroguaiaretic acid protects mice against the lethal and hepatocytolytic effects of a combined challenge with D-galN and bacterial endotoxin. J Comp Pathol1993; 108: 185—190.
102.
Vulcano M. , Meiss RP, Isturiz MADeferoxamine reduces tissue injury and lethality in LPS-treated mice. Int J Immunopharmacol2000; 8: 635—644.
Gonzalez JC , Johnson DC, Morrison DC, Freudenberg MA, Galanos C., Silverstein R.Endogenous and exogenous glucocorticoids have different roles in modulating endotoxin lethality in D-galN-sensitized mice . Infect Immun1993; 61: 970—974.
105.
Badger AM, Olivera D., Talmadge JE, Hanna N.Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism. In murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action. Circ Shock1989; 27: 51—61.
106.
Hagmann W. , Denzlinger C., Keppler D.Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action. Circ Shock1984; 14: 223—235.
107.
Konz KH, Tiegs G., Wendel A.Protection by ebselen against endotoxin shock in rats or mice sensitized by galactosamine. Prog Clin Biol Res1987; 236A: 281—288.
108.
Dankesreiter S., Hoess A., Schneider-Mergener J., Wagner H., Miethke T.Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-alpha production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J Immunol2000; 164: 4804—4811.
109.
Takahashi K., Morikawa A., Kato Y. et al. Flavonoids protect mice against two types of lethal shock induced by endotoxin. FEMS Immunol Med Microbiol2001; 31: 29—33.
110.
Van-Dien M. , Takahashi K., Mu MM et al. Protective effect of wogonin on endotoxin-induced lethal shock in D-galN-sensitized mice. Microbiol Immunol2001; 45: 751—756.
111.
Nicoletti F., Zaccone P., Di-Marco R. et al. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology1995; 85: 645—650.
112.
Gorgen I., Hartung T., Leist M. et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol1992; 149: 918—924.
113.
Nomi T., Shiota G., Isono M., Sato K., Kawasaki H.Adenovirus-mediated hepatocyte growth factor gene transfer prevents liver failure in rats. Biochem Biophys Res Commun2000; 278: 338—343.
114.
Bahrami S., Redl H., Buurman WA, Schlag G.Influence of the xanthine derivative HWA 138 on endotoxin-related coagulation disturbances: effects in non-sensitized vs D-galN sensitized rats. Thromb Haemost1992; 68: 418—423.
115.
Johnson DC, Freudenberg MAJia F., Gonzalez JC, Galanos C., Morrison DCContribution of tumor necrosis factor-alpha and glucocorticoid in hydrazine sulfate-mediated protection against endotoxin lethality. Circ Shock1994; 43: 1—8.
116.
Fomsgaard A., Galanos C.Protective properties of a human IgG preparation rich in antibodies to a wide spectrum of lipopolysaccharides. Acta Pathol Microbiol Immunol Scand1989; 97: 1114—1120.
117.
Libert C., Van-Bladel S., Brouckaert P., Shaw A., Fiers W.Involvement of the liver, but not of IL-6, in IL-1-induced desensitization to the lethal effects of tumor necrosis factor. J Immunol1991; 146: 2625—-2632.
118.
Everaerdt B., Brouckaert P., Fiers W.Recombinant IL-1 receptor antagonist protects against TNF-induced lethality in mice. J Immunol1994; 152: 5041—5049.
119.
Baumhofer JM, Beinhauer BG, Wang JE et al. Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence. Eur J Immunol1998; 28: 610—615.
120.
Barton BE, Shortall J., Jackson JVInterleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun1996; 64: 714—718.
121.
Donckier V. , Flament V., Gerard C. et al. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10. Transplantation1994; 57: 1436—1439.
122.
Santucci L. , Fiorucci S., Chiorean M. et al. Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice . Gastroenterology1996; 111: 736—744.
123.
Rogy MA, Auffenberg T., Espat NJ et al. Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med1995; 181: 2289—2293.
124.
Grundmann HJ, Hahnle U., Hegenscheid B. et al. Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J Infect Dis1992; 165: 501—505.
125.
Qureshi N. , Perera P-Y., Shen J. et al. The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events. J Immunol2003; 171: 1515—1525.
126.
Zhang GH, Mann DM, Tsai CMNeutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun1999; 67: 1353—1358.
127.
Gonzalo JA , Gonzalez-Garcia A., Kalland T., Hedlund G., Martinez C., Kroemer G.Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol1993; 23: 2372—2374.
128.
Lam C., Schutze E., Walzl H., Basalka E.Protection of mice against lethal endotoxemia by lipid X is mediated through inhibition of neutrophil function. Circ Shock1987; 22: 311—321.
129.
David SA, Silverstein R., Amura CR, Kielian N., Morrison DCLipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by Gram-negative bacteria. Antimicrob Agents Chemother1999; 43: 912—919.
130.
Lamping N. , Dettmer R., Schroder NW et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest1998; 101: 2065—2071.
131.
Bozza M., Soares MB, Bozza PT et al. The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. Eur J Immunol1998; 28: 3120—3127.
132.
Parmely MJ , Zhou WW, Edwards 3rd CK, Borcherding DR, Silverstein R., Morrison DCAdenosine and a related carbocyclic analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol1993; 151: 389—396.
133.
Borcherding DR, Peet NP, Munson HR et al. Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl) adenines. J Med Chem1996; 39: 2615—2620.
134.
Quakyi EK, Frasch CE, Buller N., Tsai CMImmunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock. J Infect Dis1999; 180: 747—754.
135.
Wielockx B. , Hochepied T., Staelens J., Van-Molle W., Brouckaert P., Libert C.Detection, characterisation and purification of a murine liver factor capable of desensitising towards the lethal activity of tumour necrosis factor. Cytokine2001; 15: 59—65.
136.
Evans TJ, Carpenter A., Moyes D., Martin R., Cohen J.Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of Gram-negative sepsis. J Infect Dis1995; 171: 153—160.
137.
Gough M., Hancock RE, Kelly NMAntiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun1996; 64: 4922—4927.
138.
Zhang WJ, Wojta J., Binder BRNotoginsensoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. Arterioscler Thromb Vasc Biol1997; 17: 465—474.
139.
Schade UFPentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock1990; 31: 171—181.
140.
Alegre ML, Gastaldello K., Abramowicz D. et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation1991; 52: 674—679.
141.
Badger AM, Olivera DL, Esser KMBeneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circ Shock1994; 44: 188—195.
142.
Arrieta O. , Ortiz-Reyes A., Rembao D., Calvillo M., Rivera E., Sotelo J.Protective effect of pentoxifylline plus thalidomide against septic shock in mice. Int J Exp Pathol1999; 80: 11—16.
Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Morgolin S., Lefkowitz SSInhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone . Int J Immunopharmacol1998; 20: 685—695.
145.
Drabick JJ , Bhattacharjee AK, Hoover DL et al. Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin agent. Antimicrob Agents Chemother1998; 42: 583—588.
146.
Bucklin SE , Lake P., Logdberg L., Morrison DCTherapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob Agents Chemother1995; 39: 1462—-1466.
147.
Schutze E. , Hildebrandt J., Liehl E., Lam C.Protection of mice from mortality caused by living and heat-killed bacteria by SDZ MRL 953. Circ Shock1994; 42: 121—127.
148.
Sakaguchi S., Tutumi E., Yokota K., Furusawa S., Sasaki K., Takayanagi Y.Preventive effects of a Chinese herb medicine (sho-saiko-to) against lethality after recombinant human tumor necrosis factor administration in mice. Microbiol Immunol1991; 35: 389—394.
149.
Olivera DL, Esser KM, Lee JC, Greig RG, Badger AMBeneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock. Circ Shock1992; 37: 301—306.
150.
Lesslauer W., Tabuchi H., Gentz R. et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol1991; 21: 2883—2886.
151.
Bourrie B., Bouaboula M., Benoit JM et al. Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand. Eur J Immunol1995 ; 25: 2882—2887.
152.
Yamazaki H. , Harada H., Matsuzaki K., Watanabe T., Saito H.Synthesis of 3-substituted 2-oxo-1,4 thiazines and evaluation of their protective effect against endotoxin shock in mice . Chem Pharm Bull1992; 40: 1025—1028.
153.
Alcorn JM, Fierer J., Chojkier M.The acute phase response protects mice from D-galN sensitization to endotoxin and tumor necrosis factor-alpha. Hepatology1992; 15: 122—129.
154.
Ogura S., Umegaki O., Genovese F. et al. Protective effect of tyrphostin AG-556 on shock induced by endotoxin or Gram-positive bacteria. Shock1999; 12: 105—110.
155.
Bucklin SE , Silverstein R., Morrison DCAn interleukin-6-induced acute-phase response does not confer protection against lipopolysaccharide lethality. Infect Immun1993; 61: 3184—3189.
156.
Morikawa A. , Kato T., Sugiyama et al. Altered expression of constitutive type and inducible heat shock proteins in response of D-galactosamine-sensitized mice to lipopolysaccharide as an experimental endotoxic shock model. FEMS Immunol1998; 21: 37—45.
157.
McCallum REHepatocyte—Kupffer cell interactions in the inhibition of hepatic gluconeogenesis by bacterial endotoxins. In: Person RJ, Majde JA. (eds) Pathophysiological Effects of Endotoxins at the Cellular Level. New York, NY: Liss, 1981; 99—113.
158.
McCallum RE , Seale TW, Stith RDInfluence of endotoxin treatment on dexamethasone induction of hepatic phosphoenolpyruvate carboxykinase. Infect Immun1983; 39: 213—219.
159.
Stith RD, McCallum REFailure of glucagon to induce hepatic phosphoenolpyruvate carboxykinase in endotoxic shock. Circ Shock1988; 26: 267—272.
160.
Topaloglu AK, Goto M., Ravindranath T., Zeller WPGalactosamine alters glucose regulation in ten-day-old rats treated with a low dose of endotoxin. Res Commun Mol Pathol Pharmacol1996; 91: 297—302.
161.
Ravindranath T., Topaloglu AK, Goto M., Zeller WPEffects of hydrazine sulfate on galactosamine-sensitized endotoxic shock in ten-day-old rats. Res Commun Mol Pathol Pharmacol1998; 99: 233—239.
162.
Underhill FPStudies in carbohydrate metabolism. I. The influence of hydrazine upon the organism, with special reference to the blood sugar content. J Biol Chem1911; 10: 159—168.
163.
Ray PD, Hanson RL, Lardy HAInhibition by hydrazine of gluconeogenesis in the rat. J Biol Chem1970, 245: 690—696.
164.
Shnyra A., Luchi M., Gao J. et al. Endotoxin in human disease and its endogenous control. In: Baue AE, Faist E, Fry DE. (eds) Multiple Organ Failure: Pathology, Prevention, and Therapy. Berlin: Springer, 2000, 114—130.
165.
Blackwood RA, Moret J., Mandl I., Turino GMEmphysema induced by intravenously administered endotoxin in an alpha1antitrypsin-deficient rat model. Am Rev Respir Dis1984; 130: 231—236.
166.
Blackwood RA, Cerreta JM, Mandl I., Turino GMAlpha1antitrypsin deficiency and increased susceptibility to elastase-induced experimental emphysema in a rat model. Am Rev Respir Dis1979; 120: 1375—1379.
167.
Luchi M., Morrison DCComparable endotoxic properties of lipopolysaccharides are manifest in diverse clinical isolates of Gram-negative bacteria. Infect Immun2000; 68: 1899—1904.
168.
Levin J., Bang FBClottable protein in Limulus: its localization and kinetics of its coagulation by endotoxin. Thromb Diath Haemorrh1968; 19: 186—197.
169.
Levin J., Tomasulo PA, Oser RSDetection of endotoxin in human blood and demonstration of an inhibitor. J Lab Clin Med1970; 75: 903—911.
170.
Galanos C. , Lüderitz O., Rietschel ETh et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem1985; 148: 1—5.
171.
Rietschel ETh, Brade L, Lindner B, Zähringer U. Biochemistry of lipopolysaccharides. In: Morrison DC, Ryan JL. (eds) Bacterial Endotoxic Lipopolysaccharides , vol I. Boca Raton, FL: CRC Press, 1992; 3—41.
172.
Takayama K., Qureshi N.Chemical structure of lipid A. In: Morrison DC, Ryan JL. (eds) Bacterial Endotoxic Lipopolysaccharides, vol I. Boca Raton, FL: CRC Press, 1992; 43—65.
173.
Matsuura M. , Yamamoto A., Kojima Y., Homma JY, Kiso M., Hasegawa W.Biological activities of chemically synthesized partial structure analogues of lipid A. J Biochem1985; 98: 1229—1237.
174.
Kotani S., Takada H., Tsujimoto M. et al. Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli Re-mutant . Infect Immun1985; 49: 225—237.
175.
Takada H., Kotani S., Tsujimoto H. et al. Immunopharmacological activities of a synthetic counterpart of a biosynthetic lipid A precursor molecule and its analogs. Infect Immun1985; 48: 219—227.
176.
Homma JY, Matsuura M., Kanegasaki Y. et al. Structural requirements of lipid A responsible for the functions: a study with chemically synthesized lipid A and its analogues. J Biochem1985; 98: 395—406.
177.
Kotani S., Takada H., Takahashi I. et al. Immunobiological activities of synthetic lipid A analogues with low endotoxicity. Infect Immun1986; 54: 673—682.
178.
Takahashi I., Kotani S., Takada H. et al. Requirement of a properly acylated beta (1-6)-D-glucosamine disaccharide bisphosphate structure for efficient manifestation of full endotoxic and associated bioactivities of lipid A. Infect Immun1987; 55: 57—68.
179.
Kumazawa Y. , Nakatsuka M., Takimoto H. et al. Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity. Infect Immun1988; 56: 149—155.
180.
Shimizu T. , Masuzawa T., Yanagihara Y., Nakamoto S., Itoh H., Achiwa K.Antitumor activity, mitogenicity, and lethal toxicity of chemically synthesized monosaccharide analogs of lipid A. J Pharmacobiodyn1988; 11: 512—518.
181.
Shimizu T. , Masuzawa T., Yanagihara Y., Shimizu C., Ikeda K., Achiwa K.Biological activities of chemically synthesized N-acetylneuraminic acid-(alpha 2-6)-monosaccharide analogs of lipid A. FEBS Lett1988; 228: 99—101.
182.
Shimizu T. , Ohtsuka Y., Masuzawa T. et al. Antitumor activity against Meth A fibrosarcoma and biologic activities of synthetic monosaccharide analogs of lipid A in mice. Mol Biother1990; 2: 110—114.
183.
Johnson AG , Tomai MA, Chen YF, Odean M.A comparison of the immunomodulating properties of two forms of monophosphoryl lipid A analogues. J Immunother1991; 10: 398—404.
184.
Masoud H., Weuntraub ST, Wang R., Cotter R., Holt SCInvestigation of the structure of lipid A from Actinobacillus actinomycetemcomitans strain Y4 and human clinical isolate PO 1021-7. Eur J Biochem1991; 200: 775—781.
185.
Lam C., Schutze E., Hildebrandt J. et al. SDZ MRL 953, a novel immunomodulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Antimicrob Agents Chemother1991; 35: 500—505.
186.
Ogawa T.Immunological properties of chemically defined lipid A from lipopolysaccharide of Porphyromonas (Bacteroides) gingivalis. Eur J Biochem1994; 219: 737—742.
187.
Moran APBiological and serological characterization of Campylobacter jejuni lipopolysaccharides with deviating core and lipid A structures. FEMS Immunol Med Microbiol1995; 11: 121—130.
188.
Matsuura M. , Shimada S., Kiso M., Hasgawa A., Nakano M.Expression of endotoxic activities by synthetic monosaccharide lipid A analogs with alkyl-branched acyl substituents. Infect Immun1995; 63: 1446—1451.
189.
Shimizu T. , Iida K., Iwamoto Y. et al. Biological activities and antitumor effects of synthetic lipid A analog linked N-acylated serine. Int J Immunopharmacol1995; 17: 425—431.
190.
Shimizu T. , Iwamoto Y., Yanagihara Y. et al. Comparison of the biological activity of synthetic N-acylated asparagine or serine linked monosaccharide lipid A analogs. Immunobiology1996; 196: 321—331.
191.
Ogawa T., Suda Y., Kashihara W. et al. Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506). Vaccine1997; 15: 1598—1605.
192.
Tanamoto K. , Azumi S., Haishima Y., Kumada H., Umemoto T.Endotoxic properties of free lipid A from Porphyromonas gingivalis. Microbiology1997 ; 143: 63—71.
193.
Sagara-Ishijima N., Furuhama K.Toxic characteristics of the synthetic lipid A derivative DT-5461 in rats and monkeys. Toxicol Sci1999; 49: 324—-331.
194.
Johnson DA , Keegan DS, Sowell CG et al. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J Med Chem1999; 42: 4640—4649.
195.
Suda Y., Kim Y., Ogawa T. et al. Chemical structure and biological activity of a lipid A component from Helicobacter pylori strain 206. J Endotoxin Res2001; 7: 95—104.
196.
Tanamoto K. , Kato H., Haishima Y., Azumi S.Biological properties of lipid A isolated from Flavobacterium meningosepticum. Clin Diagn Lab Immunol2001; 8: 522—527.
197.
Tanamoto K. , Iida T., Haishima Y., Azumi S.Endotoxic properties of lipid A from Comamonas testosteroni. Microbiology2001; 147: 1087—1094.
